多重系統退化症市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按診斷、年齡、最終用戶、地區、競爭細分

2022 年全球多重系統退化症症市場價值為 1.4973 億美元，預計在預測期內將強勁成長，到 2028 年CAGR為3.11%。多重系統退化症症是一種罕見的神經退化性疾病，與帕金森氏症和自主神經病變有共同症狀功能障礙。 MSA 的商業意義在於其對員工及其履行職業職責的能力的潛在影響。受 MSA 影響的同事可能會出現一系列症狀，包括運動困難、言語障礙和血壓不規則等自主神經功能障礙。 MSA 也稱為害羞德拉格綜合症，是一種進行性神經系統疾病，由位於脊髓和大腦的神經細胞退化引起。 MSA 的早期症狀包括血壓突然下降、肌肉僵硬、震顫、運動遲緩、言語問題和睡眠相關問題等。對於患者來說，不要忽視這些警訊並立即尋求醫療協助至關重要。如果及時診斷，MSA 管理會變得更加容易。

主要市場促進因素

診斷技術的進步

市場概況
預測期	2024-2028
2022 年市場規模	1.4973億美元
2028 年市場規模	17829萬美元
2023-2028 年CAGR	3.11%
成長最快的細分市場	亞太地區
最大的市場	北美洲

診斷技術的進步將透過提高疾病診斷的早期檢測和準確性來推動全球多重系統退化症（MSA）市場的成長。先進的影像技術和生物標記識別等尖端診斷工具使醫療保健專業人員能夠在早期階段檢測 MSA，從而促進及時干預和管理。準確且快速的診斷對於解決多重系統退化症症至關重要，多重系統退化症症是一種罕見的神經退化性疾病，具有多種臨床表現。創新診斷方法的整合不僅有助於精確的疾病識別，而且有助於制定針對性的治療策略。隨著這些技術變得更加複雜，它們提高了臨床試驗的整體效率，並加速了新型 MSA 治療的核准過程。此外，診斷能力的提高吸引了更多的研發投資，促進了製藥公司和醫療機構之間的合作。這種協同作用加速了突破性療法的開發，為市場成長創造了有利的環境。從本質上講，診斷進步和治療創新之間的共生關係將重塑全球多重系統退化症市場的格局，為利害關係人創造機會並改善患者的治療結果。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
  • 按公司分類 (2022)
• 市場地圖
  • 透過診斷
  • 按年齡
  • 按最終用戶
  • 按地區

第 6 章：北美多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲多重系統退化症市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按診斷（磁振造影 (MRI)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT)、傾斜台測試等）
  • 依年齡分類（兒童、成人、老年）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按國家/地區
• MEA：國家分析
  • 南非多重系統退化症症
  • 沙烏地阿拉伯多重系統退化症
  • 阿拉伯聯合大公國多重系統退化症症

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球多重系統退化症市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• 生物港有限公司
  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials (As Reported)
  • Key Personnel
  • SWOT Analysis
• Theravance生物製藥公司
• 住友大日本製藥株式會社
• 改變療法
• 阿斯特捷利康公司
• 百健公司
• 默克公司
• 神經孔療法公司
• 波斷療法
• Newron 製藥 SPA。

第 16 章：策略建議

Global Multiple System Atrophy Market has valued at USD 149.73 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 3.11% through 2028. Multiple System Atrophy is a rare neurodegenerative disorder that shares symptoms with both Parkinson's disease and autonomic dysfunction. The business implication of MSA lies in its potential impact on employees and their ability to fulfill their professional responsibilities. Colleagues affected by MSA may experience a range of symptoms, including motor difficulties, impaired speech, and autonomic dysfunction such as blood pressure irregularities. MSA also known as the Shy Drager Syndrome is a progressive neurological disorder that occurs from the deterioration of nerve cells located in the spinal cord and brain. The MSA early signs include sudden drop in blood pressure, muscle stiffness, tremors, bradykinesia, speech issues, and sleep related issues, among others. It is crucial for the patients to not ignore these warning signs and immediately seek medical help. MSA management becomes easier when diagnosed in time.

Key Market Drivers

Advancements in Diagnostic Technologies

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 149.73 Million
Market Size 2028	USD 178.29 Million
CAGR 2023-2028	3.11%
Fastest Growing Segment	Asia Pacific
Largest Market	North America

Advancements in diagnostic technologies are poised to propel the growth of the Global Multiple System Atrophy (MSA) Market by enhancing early detection and accuracy in disease diagnosis. Cutting-edge diagnostic tools, such as advanced imaging techniques and biomarker identification, enable healthcare professionals to detect MSA at earlier stages, facilitating timely intervention and management. Accurate and swift diagnosis is critical in addressing Multiple System Atrophy, a rare neurodegenerative disorder with diverse clinical presentations. The integration of innovative diagnostic methods not only aids in precise disease identification but also contributes to the development of targeted therapeutic strategies. As these technologies become more sophisticated, they enhance the overall efficiency of clinical trials, expediting the approval process for novel MSA treatments. Moreover, improved diagnostic capabilities attract increased investments in research and development, fostering collaboration between pharmaceutical companies and healthcare institutions. This synergy accelerates the development of groundbreaking therapies, fostering a conducive environment for market growth. In essence, the symbiotic relationship between diagnostic advancements and therapeutic innovations is set to reshape the landscape of the Global Multiple System Atrophy Market, creating opportunities for stakeholders and improving patient outcomes.

Rising Research and Development Investments

The growth of the Global Multiple System Atrophy (MSA) Market is poised to be significantly influenced by the upsurge in Research and Development (R&D) investments. Increased financial commitments to R&D initiatives underscore a commitment to advancing our understanding of MSA and developing novel therapeutic interventions. Pharmaceutical companies and research institutions are allocating substantial resources to explore innovative treatment modalities, biomarkers, and diagnostic technologies. Rising R&D investments contribute to the acceleration of clinical trials, facilitating the swift development and regulatory approval of potential MSA treatments. This influx of funds fosters collaboration among industry players, leading to synergies in expertise and resources. Furthermore, heightened R&D spending attracts top-tier talent and fosters a culture of innovation within the scientific community, propelling breakthrough discoveries and advancements in MSA research. The positive impact of these investments extends beyond scientific progress, creating a conducive market environment by boosting investor confidence and attracting additional funding. In essence, the escalating R&D investments in the MSA space not only drive scientific innovation but also play a pivotal role in shaping the future landscape of the Global Multiple System Atrophy Market, offering hope for improved patient outcomes and therapeutic solutions.

Collaborative Initiatives and Partnerships

Collaborative initiatives and partnerships are set to be key drivers in propelling the growth of the Global Multiple System Atrophy (MSA) Market. In an era of complex healthcare challenges, strategic alliances between pharmaceutical companies, research institutions, and advocacy groups are becoming increasingly prevalent. These partnerships foster a shared pool of resources, expertise, and data, creating synergies that accelerate the development of innovative solutions for MSA. Pooling knowledge and capabilities through collaborations enables faster progress in research and development efforts, leading to more efficient clinical trials and the timely introduction of new therapies. Joint initiatives also mitigate risks and financial burdens, allowing stakeholders to navigate the intricate landscape of MSA research collectively. Furthermore, collaborative efforts enhance the credibility and robustness of scientific findings, which is crucial for regulatory approvals and market acceptance. By establishing a network of shared objectives, these partnerships create a supportive ecosystem for sustained advancements, attracting further investments and fostering a competitive yet cooperative environment within the Global Multiple System Atrophy Market. In essence, collaborative initiatives are pivotal in driving the industry forward, ensuring that the collective pursuit of solutions for MSA remains at the forefront of global healthcare innovation.

Key Market Challenges

Diagnostic Complexity and Variability

The growth of the Global Multiple System Atrophy (MSA) Market may face hindrances due to the diagnostic complexity and variability inherent in the disease. MSA presents a spectrum of clinical manifestations that often overlap with other neurodegenerative disorders, posing challenges in accurate and timely diagnosis. The intricacies and subtleties of MSA symptoms can lead to misdiagnoses or delayed identification, impacting the initiation of appropriate treatments. The lack of standardized diagnostic criteria further contributes to variability in clinical assessments, hindering the consistency needed for effective research, drug development, and regulatory processes. This diagnostic uncertainty may deter investment and slow down the overall pace of innovation within the MSA market, as pharmaceutical companies and investors may be cautious about the inherent challenges in navigating such diagnostic complexities. Additionally, the variability in disease presentation among individuals makes it challenging to conduct uniform clinical trials and stratify patient populations accurately. This complexity could impede the development of targeted therapies, as a clear understanding of the disease spectrum is crucial for designing effective interventions. Thus, addressing the diagnostic intricacies of MSA is essential to unlock the full growth potential of the Global Multiple System Atrophy Market.

High Research and Development Risks

The Global Multiple System Atrophy (MSA) Market faces hindrances in growth due to the high research and development (R&D) risks associated with addressing this complex neurodegenerative disorder. Developing effective treatments for MSA demands substantial investment in R&D, often with uncertain outcomes. The intricate nature of the disease, coupled with the lack of comprehensive understanding of its underlying mechanisms, amplifies the inherent risks in drug development. Investors and pharmaceutical companies may be deterred by the considerable uncertainty in achieving successful outcomes during clinical trials. High R&D risks contribute to extended timelines, increased costs, and the potential for failures at various stages of development, posing financial challenges and diminishing the attractiveness of MSA-focused projects. Furthermore, the absence of clear biomarkers and standardized diagnostic criteria for MSA adds an additional layer of complexity, making it difficult to measure treatment efficacy accurately. This uncertainty may discourage stakeholders from committing resources to projects with unpredictable outcomes. Mitigating these high R&D risks requires collaborative efforts, increased understanding of disease pathology, and innovative approaches, as overcoming these challenges is essential for unlocking the growth potential of the Global Multiple System Atrophy Market.

Key Market Trends

Personalized Medicine and Precision Therapeutics

Personalized medicine and precision therapeutics are poised to drive significant growth in the Global Multiple System Atrophy (MSA) Market. As advancements in medical research continue, there is a growing emphasis on tailoring treatments to the unique genetic, molecular, and clinical characteristics of individual patients. This approach allows for more targeted interventions, optimizing therapeutic outcomes for those afflicted with MSA. By leveraging personalized medicine, pharmaceutical companies can develop treatments that address specific subtypes or variations within the MSA patient population. Precision therapeutics, guided by biomarker identification and genetic profiling, enable the design of therapies that are not only more effective but also have fewer side effects, enhancing overall patient quality of life. The implementation of personalized medicine strategies in MSA research and drug development enhances the efficiency of clinical trials, as patient cohorts can be more precisely defined based on their genetic and molecular profiles. This not only expedites the approval process but also fosters a more favorable regulatory environment. In essence, the integration of personalized medicine and precision therapeutics is poised to revolutionize the Global Multiple System Atrophy Market, offering tailored solutions that not only address the complexities of the disease but also pave the way for more successful and efficient therapeutic interventions.

Rise of Digital Health Solutions

The ascent of digital health solutions is set to be a driving force in the growth of the Global Multiple System Atrophy (MSA) Market. Advanced technologies, such as telemedicine, remote monitoring, and digital diagnostics, are transforming the landscape of healthcare delivery, providing novel avenues for MSA management. Digital health solutions offer the potential to enhance patient care through remote monitoring of symptoms, facilitating real-time data collection and analysis. This not only enables healthcare professionals to gain deeper insights into the progression of MSA but also allows for more proactive and personalized interventions. Telehealth platforms create opportunities for improved patient engagement, enabling individuals with MSA to access specialized care remotely. This not only addresses geographical barriers but also enhances the overall efficiency of healthcare delivery. Moreover, the integration of digital health tools in clinical trials enhances the precision and reliability of data collection, expediting the research and development process for new MSA treatments. As the healthcare industry increasingly embraces digital solutions, the Global Multiple System Atrophy Market stands to benefit from heightened efficiency, improved patient outcomes, and accelerated innovation in the quest for effective therapies.

Segmental Insights

Diagnosis Insights

Based on the Diagnosis, the Magnetic Resonance Imaging segment is anticipated to witness substantial market growth throughout the forecast period. Magnetic Resonance Imaging (MRI) is poised to be a catalyst for the growth of the Global Multiple System Atrophy (MSA) Market. As a non-invasive and advanced imaging technique, MRI plays a pivotal role in the early and accurate diagnosis of MSA, contributing to improved patient outcomes and streamlined clinical trials. MRI enables the visualization of structural abnormalities and changes in the brain associated with MSA, providing clinicians with valuable insights into the disease's progression. This diagnostic precision is crucial for distinguishing MSA from other neurodegenerative disorders and facilitating prompt intervention. In addition to its diagnostic utility, MRI is becoming increasingly instrumental in advancing MSA research and drug development. It serves as a key tool for monitoring treatment efficacy and disease progression in clinical trials, offering objective and quantifiable measures that enhance the efficiency of these studies. The widespread adoption of MRI technology in both clinical practice and research initiatives creates a synergistic effect, fostering collaboration between healthcare institutions, pharmaceutical companies, and imaging technology developers. As MRI continues to play a pivotal role in unraveling the complexities of MSA, its integration is poised to drive innovation, accelerate therapeutic advancements, and ultimately contribute to the growth of the Global Multiple System Atrophy Market.

End User Insights

Based on the End User segment, the Hospitals segment has been the dominant force in the market. Hospitals are positioned as key drivers in fueling the growth of the Global Multiple System Atrophy (MSA) Market. As primary hubs for healthcare delivery, hospitals play a central role in the diagnosis, treatment, and management of MSA. The rising prevalence of MSA, coupled with increasing awareness and diagnostic capabilities, results in a growing number of patients seeking care in hospital settings. Hospitals contribute significantly to the expansion of the MSA market by serving as crucial centers for clinical trials and research initiatives. These institutions often collaborate with pharmaceutical companies, research organizations, and other stakeholders to conduct studies, advancing our understanding of the disease and facilitating the development of novel therapeutic interventions. Moreover, the demand for specialized MSA care within hospital settings fosters the growth of dedicated neurology departments and clinics. This specialization not only enhances patient outcomes but also attracts investments in infrastructure, technology, and healthcare professionals, creating a robust ecosystem for MSA-focused advancements. As hospitals increasingly adopt cutting-edge technologies, telemedicine, and interdisciplinary approaches, they become pivotal players in driving innovation and shaping the trajectory of the Global Multiple System Atrophy Market, ultimately improving the quality of care and expanding opportunities for stakeholders in the healthcare industry.

Regional Insights

North America, specifically the Multiple System Atrophy Market, dominated the market in 2022, primarily due to North America is poised to be a driving force behind the growth of the Global Multiple System Atrophy (MSA) Market. The region's advanced healthcare infrastructure, coupled with robust research and development initiatives, positions it as a key player in shaping the trajectory of MSA-focused advancements. In the United States and Canada, there is a high prevalence of neurodegenerative disorders, including MSA, prompting increased attention and investment in addressing these complex diseases. The presence of leading pharmaceutical companies, research institutions, and healthcare organizations in North America fosters innovation and accelerates the development of novel therapies for MSA. Moreover, the region's well-established regulatory frameworks and clinical trial infrastructure streamline the approval process for new treatments, attracting investments and fostering a conducive environment for market growth. Collaborations between academia, industry, and government entities in North America contribute to a comprehensive understanding of MSA, driving progress in diagnostic technologies, precision medicine, and therapeutic interventions. As a result, the North American region emerges as a hub for MSA research, playing a pivotal role in not only advancing patient care but also propelling the Global Multiple System Atrophy Market forward.

Key Market Players

Biohaven Ltd.

Theravance Biopharma

Sumitomo Dainippon Pharma Co., Ltd.

Alterity Therapeutics

AstraZeneca plc.

Biogen

Merck & Co., Inc.

Neuropore Therapies, Inc.

WaveBreak Therapeutics

Newron Pharmaceuticals SPA.

Report Scope:

In this report, the Global Multiple System Atrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiple System Atrophy Market, By Diagnosis:

• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Tilt Table Test
• Others

Multiple System Atrophy Market, By Age:

• Pediatric
• Adults
• Geriatric

Multiple System Atrophy Market, By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Multiple System Atrophy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Multiple System Atrophy Market.

Available Customizations:

• Global Multiple System Atrophy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multiple System Atrophy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 5.2.2. By Age (Pediatric, Adults, Geriatric)
  • 5.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Diagnosis
  • 5.3.2 By Age
  • 5.3.3 By End User
  • 5.3.4 By Region

6. North America Multiple System Atrophy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 6.2.2. By Age (Pediatric, Adults, Geriatric)
  • 6.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiple System Atrophy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Age
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Multiple System Atrophy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Age
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Multiple System Atrophy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Age
      • 6.3.3.2.3. By End User

7. Europe Multiple System Atrophy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 7.2.2. By Age (Pediatric, Adults, Geriatric)
  • 7.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Multiple System Atrophy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Age
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Multiple System Atrophy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Age
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Multiple System Atrophy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Age
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Multiple System Atrophy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Age
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Multiple System Atrophy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Age
      • 7.3.5.2.3. By End User

8. Asia-Pacific Multiple System Atrophy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 8.2.2. By Age (Pediatric, Adults, Geriatric)
  • 8.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multiple System Atrophy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Age
      • 8.3.1.2.3. By End User
  • 8.3.2. India Multiple System Atrophy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Age
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Multiple System Atrophy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Age
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Multiple System Atrophy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Age
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Multiple System Atrophy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Age
      • 8.3.5.2.3. By End User

9. South America Multiple System Atrophy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 9.2.2. By Age (Pediatric, Adults, Geriatric)
  • 9.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multiple System Atrophy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Age
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Multiple System Atrophy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Age
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Multiple System Atrophy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Age
      • 9.3.3.2.3. By End User

10. Middle East and Africa Multiple System Atrophy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others)
  • 10.2.2. By Age (Pediatric, Adults, Geriatric)
  • 10.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multiple System Atrophy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Age
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Multiple System Atrophy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Age
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Multiple System Atrophy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Age
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Multiple System Atrophy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biohaven Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Theravance Biopharma
• 15.3. Sumitomo Dainippon Pharma Co., Ltd.
• 15.4. Alterity Therapeutics
• 15.5. AstraZeneca plc.
• 15.6. Biogen
• 15.7. Merck & Co., Inc.
• 15.8. Neuropore Therapies, Inc.
• 15.9. WaveBreak Therapeutics
• 15.10. Newron Pharmaceuticals SPA.

16. Strategic Recommendations